Cidara Price To Sales Ratio vs Cash Per Share Analysis

CDTX Stock

USD 20.21 0.01 0.05%

Cidara Therapeutics financial indicator trend analysis is way more than just evaluating Cidara Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cidara Therapeutics is a good investment. Please check the relationship between Cidara Therapeutics Price To Sales Ratio and its Cash Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

Price To Sales Ratio vs Cash Per Share

Price To Sales Ratio vs Cash Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cidara Therapeutics Price To Sales Ratio account and Cash Per Share. At this time, the significance of the direction appears to have very week relationship.

The correlation between Cidara Therapeutics' Price To Sales Ratio and Cash Per Share is 0.26. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Cash Per Share in the same time period over historical financial statements of Cidara Therapeutics, assuming nothing else is changed. The correlation between historical values of Cidara Therapeutics' Price To Sales Ratio and Cash Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Cidara Therapeutics are associated (or correlated) with its Cash Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash Per Share has no effect on the direction of Price To Sales Ratio i.e., Cidara Therapeutics' Price To Sales Ratio and Cash Per Share go up and down completely randomly.

Correlation Coefficient

0.26

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Cidara Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cidara Therapeutics sales, a figure that is much harder to manipulate than other Cidara Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Cash Per Share

Most indicators from Cidara Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cidara Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.At this time, Cidara Therapeutics' Tax Provision is fairly stable compared to the past year. Enterprise Value is likely to rise to about 54.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 14 M in 2024.

Cidara Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Property Plant And Equipment Gross	Common Stock	Property Plant Equipment
Total Assets		0.73	0.46	0.41	0.73	-0.94	-0.47	0.79	0.96	0.53	0.36	0.32	0.47	0.96	0.4	0.41	0.27	0.55	0.43	1.0	0.28	0.83	0.35	0.31	0.34	0.24
Short Long Term Debt Total	0.73		0.06	0.1	0.75	-0.74	-0.09	0.64	0.77	0.23	0.41	0.27	0.53	0.77	-0.03	-0.13	0.0	0.23	0.04	0.74	0.08	0.72	0.0	-0.02	-0.11	0.12
Other Current Liab	0.46	0.06		0.93	-0.25	-0.17	-0.92	0.55	0.22	0.93	0.51	0.57	0.52	0.22	0.95	0.69	0.63	0.83	0.97	0.44	0.8	-0.08	0.84	0.8	0.94	-0.21
Total Current Liabilities	0.41	0.1	0.93		-0.3	-0.09	-0.92	0.59	0.15	0.98	0.64	0.64	0.47	0.15	0.96	0.45	0.54	0.8	0.98	0.38	0.8	-0.13	0.89	0.84	0.94	-0.39
Total Stockholder Equity	0.73	0.75	-0.25	-0.3		-0.9	0.23	0.41	0.88	-0.16	-0.08	-0.16	0.11	0.88	-0.31	-0.04	-0.21	-0.07	-0.3	0.75	-0.31	0.97	-0.27	-0.28	-0.37	0.48
Net Debt	-0.94	-0.74	-0.17	-0.09	-0.9		0.18	-0.62	-0.99	-0.24	-0.11	-0.07	-0.32	-0.99	-0.11	-0.29	-0.08	-0.3	-0.12	-0.95	-0.02	-0.95	-0.09	-0.06	-0.05	-0.44
Retained Earnings	-0.47	-0.09	-0.92	-0.92	0.23	0.18		-0.58	-0.23	-0.89	-0.69	-0.74	-0.55	-0.23	-0.95	-0.67	-0.78	-0.95	-0.97	-0.44	-0.82	0.06	-0.7	-0.66	-0.94	0.28
Accounts Payable	0.79	0.64	0.55	0.59	0.41	-0.62	-0.58		0.65	0.64	0.72	0.68	0.52	0.65	0.51	0.3	0.38	0.63	0.57	0.78	0.29	0.52	0.4	0.33	0.42	-0.18
Cash	0.96	0.77	0.22	0.15	0.88	-0.99	-0.23	0.65		0.29	0.17	0.12	0.37	1.0	0.15	0.28	0.1	0.35	0.17	0.97	0.07	0.94	0.12	0.1	0.09	0.39
Non Current Assets Total	0.53	0.23	0.93	0.98	-0.16	-0.24	-0.89	0.64	0.29		0.6	0.59	0.52	0.29	0.93	0.44	0.47	0.78	0.95	0.5	0.79	0.0	0.91	0.87	0.91	-0.28
Non Currrent Assets Other	0.36	0.41	0.51	0.64	-0.08	-0.11	-0.69	0.72	0.17	0.6		0.97	0.56	0.17	0.54	0.21	0.64	0.72	0.61	0.33	0.53	0.01	0.27	0.23	0.47	-0.44
Other Assets	0.32	0.27	0.57	0.64	-0.16	-0.07	-0.74	0.68	0.12	0.59	0.97		0.52	0.12	0.58	0.4	0.75	0.76	0.66	0.3	0.54	-0.06	0.26	0.24	0.53	-0.34
Long Term Debt	0.47	0.53	0.52	0.47	0.11	-0.32	-0.55	0.52	0.37	0.52	0.56	0.52		0.37	0.46	0.35	0.41	0.67	0.51	0.46	0.39	0.13	0.27	0.25	0.45	-0.15
Cash And Short Term Investments	0.96	0.77	0.22	0.15	0.88	-0.99	-0.23	0.65	1.0	0.29	0.17	0.12	0.37		0.15	0.28	0.1	0.35	0.17	0.97	0.07	0.94	0.12	0.1	0.09	0.39
Common Stock Shares Outstanding	0.4	-0.03	0.95	0.96	-0.31	-0.11	-0.95	0.51	0.15	0.93	0.54	0.58	0.46	0.15		0.62	0.64	0.84	0.98	0.38	0.79	-0.14	0.84	0.78	0.99	-0.35
Non Current Liabilities Total	0.41	-0.13	0.69	0.45	-0.04	-0.29	-0.67	0.3	0.28	0.44	0.21	0.4	0.35	0.28	0.62		0.76	0.68	0.63	0.4	0.43	0.08	0.3	0.3	0.64	0.23
Other Current Assets	0.27	0.0	0.63	0.54	-0.21	-0.08	-0.78	0.38	0.1	0.47	0.64	0.75	0.41	0.1	0.64	0.76		0.78	0.65	0.25	0.65	-0.09	0.19	0.11	0.6	-0.25
Other Stockholder Equity	0.55	0.23	0.83	0.8	-0.07	-0.3	-0.95	0.63	0.35	0.78	0.72	0.76	0.67	0.35	0.84	0.68	0.78		0.87	0.52	0.75	0.09	0.53	0.5	0.82	-0.18
Total Liab	0.43	0.04	0.97	0.98	-0.3	-0.12	-0.97	0.57	0.17	0.95	0.61	0.66	0.51	0.17	0.98	0.63	0.65	0.87		0.4	0.8	-0.12	0.84	0.8	0.97	-0.3
Total Current Assets	1.0	0.74	0.44	0.38	0.75	-0.95	-0.44	0.78	0.97	0.5	0.33	0.3	0.46	0.97	0.38	0.4	0.25	0.52	0.4		0.25	0.85	0.32	0.28	0.31	0.26
Other Liab	0.28	0.08	0.8	0.8	-0.31	-0.02	-0.82	0.29	0.07	0.79	0.53	0.54	0.39	0.07	0.79	0.43	0.65	0.75	0.8	0.25		-0.17	0.69	0.62	0.77	-0.31
Net Tangible Assets	0.83	0.72	-0.08	-0.13	0.97	-0.95	0.06	0.52	0.94	0.0	0.01	-0.06	0.13	0.94	-0.14	0.08	-0.09	0.09	-0.12	0.85	-0.17		-0.12	-0.14	-0.2	0.43
Property Plant And Equipment Net	0.35	0.0	0.84	0.89	-0.27	-0.09	-0.7	0.4	0.12	0.91	0.27	0.26	0.27	0.12	0.84	0.3	0.19	0.53	0.84	0.32	0.69	-0.12		0.97	0.85	-0.24
Property Plant And Equipment Gross	0.31	-0.02	0.8	0.84	-0.28	-0.06	-0.66	0.33	0.1	0.87	0.23	0.24	0.25	0.1	0.78	0.3	0.11	0.5	0.8	0.28	0.62	-0.14	0.97		0.82	-0.06
Common Stock	0.34	-0.11	0.94	0.94	-0.37	-0.05	-0.94	0.42	0.09	0.91	0.47	0.53	0.45	0.09	0.99	0.64	0.6	0.82	0.97	0.31	0.77	-0.2	0.85	0.82		-0.26
Property Plant Equipment	0.24	0.12	-0.21	-0.39	0.48	-0.44	0.28	-0.18	0.39	-0.28	-0.44	-0.34	-0.15	0.39	-0.35	0.23	-0.25	-0.18	-0.3	0.26	-0.31	0.43	-0.24	-0.06	-0.26

Click cells to compare fundamentals

Cidara Therapeutics Account Relationship Matchups

Cidara Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	69.0M	60.4M	75.3M	47.6M	67.0M	71.9M
Short Long Term Debt Total	11.7M	8.0M	5.1M	1.3M	4.9M	5.5M
Other Current Liab	7.7M	11.2M	13.9M	12.6M	17.9M	18.8M
Total Current Liabilities	30.2M	38.6M	34.0M	30.0M	67.4M	70.8M
Total Stockholder Equity	37.8M	10.7M	21.6M	(2.9M)	(8.2M)	(7.8M)
Net Debt	(48.5M)	(28.0M)	(57.2M)	(31.4M)	(30.9M)	(32.4M)
Retained Earnings	(259.8M)	(334.7M)	(377.2M)	(407.0M)	(441.4M)	(419.4M)
Accounts Payable	1.9M	4.6M	1.3M	1.4M	3.8M	2.6M
Cash	60.3M	35.9M	62.3M	32.7M	35.8M	44.5M
Non Current Assets Total	3.2M	3.2M	3.6M	2.5M	6.2M	6.5M
Non Currrent Assets Other	1.1M	2.0M	533K	634K	1.0M	767K
Other Assets	1.3M	1.1M	2.9M	1.1M	1.2M	905.3K
Cash And Short Term Investments	60.3M	35.9M	62.3M	32.7M	35.8M	44.5M
Common Stock Shares Outstanding	1.5M	2.1M	2.6M	3.5M	4.4M	4.6M
Liabilities And Stockholders Equity	69.0M	60.4M	75.3M	47.6M	67.0M	71.9M
Non Current Liabilities Total	942K	11.1M	19.7M	20.5M	7.8M	8.5M
Other Current Assets	5.5M	10.1M	6.7M	13.1M	2.7M	4.5M
Other Stockholder Equity	297.7M	345.4M	398.7M	404.1M	433.2M	262.2M
Total Liab	31.1M	49.7M	53.8M	50.5M	75.2M	79.0M
Total Current Assets	65.8M	57.2M	71.7M	45.1M	60.9M	69.2M
Net Tangible Assets	37.8M	10.7M	21.6M	(2.9M)	(2.6M)	(2.5M)
Property Plant And Equipment Net	2.1M	1.2M	2.5M	1.4M	5.1M	5.4M
Property Plant And Equipment Gross	2.1M	1.2M	5.8M	222K	8.3M	8.7M
Property Plant Equipment	429K	342K	2.5M	222K	199.8K	189.8K
Retained Earnings Total Equity	(218.7M)	(259.8M)	(334.7M)	(407.0M)	(366.3M)	(348.0M)
Capital Surpluse	277.9M	297.7M	345.4M	404.1M	464.7M	293.1M
Net Receivables	5.5M	11.2M	5.4M	5.8M	16.2M	17.1M
Short Long Term Debt	9.9M	10.0M	7.0M	2.6M	2.3M	2.2M
Short Term Debt	10.8M	8.9M	4.9M	1.2M	2.6M	5.1M
Net Invested Capital	47.8M	17.7M	24.2M	(2.9M)	(8.2M)	(7.8M)
Net Working Capital	35.6M	18.6M	37.7M	15.1M	(6.6M)	(6.2M)
Current Deferred Revenue	9.8M	13.9M	13.9M	14.6M	25.1M	15.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cidara Price To Sales Ratio vs Cash Per Share Analysis

Price To Sales Ratio vs Cash Per Share

Price To Sales Ratio vs Cash Per Share Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Cash Per Share

Cidara Therapeutics fundamental ratios Correlations

Cidara Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cidara Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Cidara Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 0.99	Common Stock Shares Outstanding
Non Current Assets Total	+ 0.98	Total Current Liabilities
Total Liab	+ 0.98	Total Current Liabilities
Total Liab	+ 0.98	Common Stock Shares Outstanding

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Liab	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Common Stock Shares Outstanding	- 0.95	Retained Earnings
Net Tangible Assets	- 0.95	Net Debt